Progressive Pulmonary Fibrosis
Admilparant slows lung function decline in IPF, progressive PF
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.
Positive topline data reported in phase 3 trial of nerandomilast in progressive PF
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.
Nintedanib slows symptom worsening in progressive pulmonary fibrosis
Among patients with progressive pulmonary fibrosis, taking nintedanib for 52 weeks lowered the degree of worsened dyspnea, fatigue and cough compared with placebo, according to results published in European Respiratory Journal.
FDA grants breakthrough designation to progressive pulmonary fibrosis treatment
The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that lowered the rate of percent-predicted FVC decline among patients with progressive pulmonary fibrosis.